{"id":102,"date":"2025-10-20T16:11:03","date_gmt":"2025-10-20T16:11:03","guid":{"rendered":"https:\/\/peanutimmunotherapy.scot\/?page_id=102"},"modified":"2025-10-20T16:11:03","modified_gmt":"2025-10-20T16:11:03","slug":"news","status":"publish","type":"page","link":"https:\/\/peanutimmunotherapy.scot\/?page_id=102","title":{"rendered":"News"},"content":{"rendered":"<ul class=\"wp-block-latest-posts__list has-dates wp-block-latest-posts\"><li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/peanutimmunotherapy.scot\/?p=116\">Vitesse trial<\/a><time datetime=\"2025-12-23T23:31:53+00:00\" class=\"wp-block-latest-posts__post-date\">December 23, 2025<\/time><div class=\"wp-block-latest-posts__post-excerpt\">VITESSE trial of epicutaneous (patch, in other words) immunotherapy for peanut allergy has reported successful results &#8211; this is the largest food immunotherapy trial ever performed, across US, Canada, Europe and Australia. Results have not been formally presented or published yet. This is a commercial product, called Viaskin. 654 patients between the ages of 4\u2026 <a class=\"wp-block-latest-posts__read-more\" href=\"https:\/\/peanutimmunotherapy.scot\/?p=116\" rel=\"noopener noreferrer\">Read more<span class=\"screen-reader-text\">: Vitesse trial<\/span><\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/peanutimmunotherapy.scot\/?p=108\">Systematic Review of Omalizumab and OIT<\/a><time datetime=\"2025-10-20T16:53:19+00:00\" class=\"wp-block-latest-posts__post-date\">October 20, 2025<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Italian review of 11 studies of the use of the Anti-IgE medicine Omalizumab in oral immunotherapy (OIT) &#8211; Pharmaceuticals 2025 Mar 20;18(3):437. 3 studies looked at peanut allergy. Schneider&#8217;s study looked at 13 children aged 8-16. On the first day of OIT, all passed a 500mg dose of peanut flour! Within 8 weeks, all but\u2026 <a class=\"wp-block-latest-posts__read-more\" href=\"https:\/\/peanutimmunotherapy.scot\/?p=108\" rel=\"noopener noreferrer\">Read more<span class=\"screen-reader-text\">: Systematic Review of Omalizumab and OIT<\/span><\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/peanutimmunotherapy.scot\/?p=105\">Omalizumab and early life OIT<\/a><time datetime=\"2025-10-20T16:34:29+00:00\" class=\"wp-block-latest-posts__post-date\">October 20, 2025<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Helen Brough et al review the use of the Anti-IgE antibody to improve outcomes in oral immunotherapy (OIT). [J Allergy Clin Immunol Pract\u00a02025 Apr;13(4):731-739] To begin with though, they review data on early life (pre-school) OIT. They suggest adherence is better, which I&#8217;m not convinced about, but point out that if you start early, you\u2026 <a class=\"wp-block-latest-posts__read-more\" href=\"https:\/\/peanutimmunotherapy.scot\/?p=105\" rel=\"noopener noreferrer\">Read more<span class=\"screen-reader-text\">: Omalizumab and early life OIT<\/span><\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/peanutimmunotherapy.scot\/?p=98\">Predicting remission<\/a><time datetime=\"2025-02-10T13:24:15+00:00\" class=\"wp-block-latest-posts__post-date\">February 10, 2025<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Article from Australia &#8211; remission is defined as being able to discontinue treatment for at least 8 weeks and still not have any reaction to peanut. This was a group of 162 children treated between the ages of 1 and 10 with peanut flour +\/-probiotics, not Palforzia. The higher your peanut blood IgE level is\u2026 <a class=\"wp-block-latest-posts__read-more\" href=\"https:\/\/peanutimmunotherapy.scot\/?p=98\" rel=\"noopener noreferrer\">Read more<span class=\"screen-reader-text\">: Predicting remission<\/span><\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/peanutimmunotherapy.scot\/?p=94\">Safety of peanut OIT in young children in a clinic setting<\/a><time datetime=\"2025-01-20T15:11:42+00:00\" class=\"wp-block-latest-posts__post-date\">January 20, 2025<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Study from Canada &#8211; 69 children under the age of 3 reached maintenance dose of peanut over a median of 29\u00a0weeks (so slightly more than 6 months, on average). One patient had a peanut ingestion-related emergency department (ED) visit requiring adrenaline during initial dose escalation (first day). During the first year of maintenance phase, no\u2026 <a class=\"wp-block-latest-posts__read-more\" href=\"https:\/\/peanutimmunotherapy.scot\/?p=94\" rel=\"noopener noreferrer\">Read more<span class=\"screen-reader-text\">: Safety of peanut OIT in young children in a clinic setting<\/span><\/a><\/div><\/li>\n<\/ul>","protected":false},"excerpt":{"rendered":"","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-102","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/peanutimmunotherapy.scot\/index.php?rest_route=\/wp\/v2\/pages\/102","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/peanutimmunotherapy.scot\/index.php?rest_route=\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/peanutimmunotherapy.scot\/index.php?rest_route=\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/peanutimmunotherapy.scot\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/peanutimmunotherapy.scot\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=102"}],"version-history":[{"count":1,"href":"https:\/\/peanutimmunotherapy.scot\/index.php?rest_route=\/wp\/v2\/pages\/102\/revisions"}],"predecessor-version":[{"id":104,"href":"https:\/\/peanutimmunotherapy.scot\/index.php?rest_route=\/wp\/v2\/pages\/102\/revisions\/104"}],"wp:attachment":[{"href":"https:\/\/peanutimmunotherapy.scot\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=102"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}